21st.BIO Competitors and Similar CompaniesClear all

21st.BIO's competitors and similar companies include Centogene, Bota Biosciences, Codexis and CN Bio.

	21st.BIO 21st.BIO is a bioproduction company focused on the production optimization of proteins and peptides for the food, materials, and agricultural industries.	Centogene Centogene is a biotechnology company that provides services in the field of genetic diagnostics for rare hereditary diseases.	Bota Biosciences Bota Biosciences (also known as Hangzhou Enhe Biotechnology, 杭州恩和生物科技有限公司) is a company that provides an integrated bio-manufacturing platform.	Codexis Codexis is a protein engineering company that develops enzymes for pharmaceutical, food, and medical applications.	CN Bio CN Bio Innovations (formerly known as Zyoxel) is a company that develops organ-on-a-chip systems for human drug discovery and preclinical research.
Founding Date	Founding Date 2020	Founding Date 2005	Founding Date 2019	Founding Date 2002	Founding Date 2008
Type	Type Private	Type Public	Type Private	Type Public	Type Subsidiary
Tags	Tags Technology bioengineering biotech platform	Tags Technology bioengineering biotech genetics medical diagnostics platform	Tags Technology bioengineering biotech chemicals platform supplements	Tags Technology bioengineering biotech pharma platform	Tags Technology bioengineering biotech drug development medtech platform
Locations	Locations Virum, DK HQ	Locations Rostock, DE HQ Wien, AT Berlin, DE Frankfurt Am Main, DE Hamburg, DE Greater Noida, IN Dubai, AE see more	Locations Hangzhou, CN HQ Pudong, CN Shandong, CN Lafayette, US	Locations Redwood City, US HQ	Locations Milton, GB HQ
Employees	Employees 635% increase	Employees 80823% increase	Employees 34	Employees 1888% increase	Employees 576% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 9.4 m	Valuation ($) N/A	Valuation ($) 226.3 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €48.5m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) $70.4m (FY, 2025)	Revenue (est.) £3.5m (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods €29.1m (FY, 2023)	Cost of goods N/A	Cost of goods $9.3m (FY, 2025)	Cost of goods £1.4m (FY, 2024)
Gross profit	Gross profit N/A	Gross profit €23.7m (FY, 2023)	Gross profit N/A	Gross profit $61m (FY, 2025)	Gross profit £2.1m (FY, 2024)
Net income	Net income N/A	Net income (€35.5m) (FY, 2023)	Net income N/A	Net income ($44m) (FY, 2025)	Net income (£6.3m) (FY, 2024)
Funding
Latest funding round	Latest funding round $ 97.1m (over 4 years ago)	Latest funding round N/A	Latest funding round $ 100m (almost 5 years ago)	Latest funding round N/A	Latest funding round N/A
Total funding raised	Total funding raised $ 97.1m	Total funding raised $ 29.6m	Total funding raised $ 115m	Total funding raised $ 87m	Total funding raised $ 11.5m